David Mosmuller, MD, PhD, Co-Founder and CEO
David Mosmuller is a medical doctor with a business mindset who has extensive experience in team management, clinical research, life sciences, medicine, regulatory affairs, and pharmacovigilance. He has a PhD in medicine from the VU University Amsterdam and worked in the past within the medical affairs departments of Sanquin Plasma Products and Novo Nordisk in the Netherlands. With SanaGen he aims to disrupt the market by developing affordable gene therapy products for patients with rare bleeding disorders and making these therapies globally available.
Matthew Hotchko, PhD, MBA Co-Founder and Board Member
Matthew Hotchko is a biotechnology industry veteran, who has helped a number of companies throughout his career, with a particular focus on how new technology can disrupt current marketplaces. He has spent most of his career in the plasma protein industry and is an expert in that space. Dr. Hotchko received his MS and PhD degrees in Biochemistry from the University of California, San Diego and his MBA from San Diego State University. He graduated with a Bachelor’s of Science degree in Chemistry from Gonzaga University.
Bas Blits, PhD, Senior Scientist
Bas Blits is a passionate scientist with 20+ years of experience in the field of gene therapy. After obtaining his PhD on gene therapeutic strategies for spinal cord repair he went for his Postdoctoral training to the Miami Project to Cure Paralysis before joining AMT (currently UniQure), where he spent 10 years of his career. At UniQure he was head of the neurobiology research department with several research programs in the pipeline up till the preclinical stage. He later worked at DegenRx, developing a gene therapeutic strategy against amyloid beta oligomers for Alzheimer’s Disease and is currently also working part-time at Syngle Therapeutics for Parkinson’s disease. At SanaGen, Bas is responsible for the research and development of gene therapy for rare bleeding disorders.